MCCQE Part I obstetrics & gynecology questions

First-trimester ultrasound crown-rump length is the most accurate method for dating a pregnancy. When the discrepancy between LMP-based dating and first-trimester ultrasound dating exceeds 5-7 days (using crown-rump length before 14 weeks), the ultrasound estimate should be used to redefine the estimated due date, because it is less subject to error from variable ovulation timing or recall bias. Regular cycles improve the reliability of LMP dating but do not override a significant ultrasound discrepancy. This has direct clinical importance for timing of screening tests, growth assessment, and decisions about induction for postdates.

• A. A repeat scan is unnecessary; the discrepancy threshold has already been met and redating should occur now.
• C. Dating should be based on accuracy, not on a strategy to avoid a particular clinical outcome.
• D. Averaging is not a validated method and discards the more accurate ultrasound measurement.
• E. Regular cycles alone do not make LMP dating more reliable than a discrepant first-trimester ultrasound.

Routine first-trimester prenatal bloodwork in Canada includes ABO/Rh blood typing with an antibody (indirect Coombs) screen, complete blood count, screening for immunity to rubella and varicella, and universal screening for HIV, hepatitis B surface antigen, and syphilis regardless of symptoms or perceived risk. Universal offering of these infectious screens allows early identification and treatment or intervention to reduce vertical transmission. Chlamydia and gonorrhea screening is also offered based on risk factors, not only when symptomatic. A Pap smear is not routinely repeated in pregnancy if the patient is up to date per Canadian cervical screening guidelines.

• B. A Pap smear is not required at this visit since she had one 2 years ago and is asymptomatic and up to date.
• C. Screening should be risk-based or routine, not reserved only for symptomatic patients.
• D. Routine first-trimester bloodwork does not include glucose testing; gestational diabetes screening is done at 24-28 weeks unless risk factors are present.
• E. Universal infectious disease screening is recommended in pregnancy regardless of symptoms, not deferred.

Diabetes Canada's preferred two-step approach for average-risk pregnant women screens between 24 and 28 weeks gestation with a 50-gram glucose challenge test (GCT), measuring plasma glucose 1 hour after the oral glucose load, without prior fasting. If the 1-hour value falls in an intermediate range, a diagnostic 75-gram oral glucose tolerance test is then performed as the second step; if it is markedly elevated, gestational diabetes is diagnosed without further testing. HbA1c and fasting or random glucose are not part of the standard screening protocol for average-risk women in this gestational window. The 75-gram OGTT alone is the preferred one-step alternative, not the first step of the preferred two-step approach.

• B. The 75-gram OGTT is the second diagnostic step in the two-step approach, or used as a one-step alternative, not the first screening test here.
• C. Random capillary glucose lacks the sensitivity and standardization needed for gestational diabetes screening.
• D. Fasting plasma glucose alone is not a validated screening test for gestational diabetes at 24-28 weeks.
• E. HbA1c is unreliable in pregnancy due to physiologic changes in red cell turnover and is not used for routine gestational diabetes screening.

Using Diabetes Canada's diagnostic criteria for the 75-gram oral glucose tolerance test, gestational diabetes is diagnosed if any one of the following is met or exceeded: fasting plasma glucose 5.3 mmol/L, 1-hour 10.6 mmol/L, or 2-hour 9.0 mmol/L. In this case, the 1-hour value of 10.8 mmol/L exceeds the threshold, which is sufficient on its own to make the diagnosis even though the fasting and 2-hour values are below their respective thresholds. The elevated 1-hour glucose challenge test result appropriately triggered the diagnostic oral glucose tolerance test as part of the two-step approach. No repeat testing or HbA1c is needed once diagnostic criteria are met.

• A. A normal fasting glucose does not exclude the diagnosis because the diagnosis can be made on any single abnormal value, including the 1-hour or 2-hour result.
• B. The diagnosis has already been confirmed by the OGTT; repeat testing is not indicated.
• C. Impaired fasting glucose is not the correct interpretation since the fasting value is normal and an elevated 1-hour value already meets the criteria for gestational diabetes.
• D. HbA1c is not required for diagnosis once OGTT criteria are met and is unreliable in pregnancy.

Routine antenatal prophylaxis with Rh immunoglobulin (anti-D immunoglobulin, e.g., WinRho) is recommended at 28 weeks gestation for all Rh-negative women who are not already sensitized, regardless of the partner's blood type, because fetal Rh status is usually unknown and partner testing can be unreliable or unavailable. A negative antibody screen confirms the woman is not yet sensitized, which is the indication for giving prophylaxis, not a reason to withhold it. A second dose is also given within 72 hours after delivery if the newborn is confirmed Rh-positive. Rh immunoglobulin is additionally indicated after any sensitizing event in pregnancy, such as amniocentesis, miscarriage, or abdominal trauma.

• B. Antenatal prophylaxis at 28 weeks is standard in addition to postpartum dosing, not a replacement for it.
• C. Rh immunoglobulin is given routinely at 28 weeks and after any sensitizing event, not only tied to amniocentesis.
• D. Waiting for partner testing is unnecessary and could delay prophylaxis; standard practice gives the dose at 28 weeks regardless.
• E. A negative antibody screen means prophylaxis is indicated, not contraindicated; it confirms the woman is unsensitized.

Universal screening for group B Streptococcus (GBS) colonization is performed with a combined vaginal-rectal swab culture at 36 to 37 weeks gestation, timed to predict colonization status at delivery. Women who screen positive should receive intrapartum antibiotic prophylaxis, typically intravenous penicillin G, to reduce the risk of early-onset neonatal GBS disease. Other accepted indications for prophylaxis regardless of screening result include GBS bacteriuria in the current pregnancy, a previous infant with invasive GBS disease, or unknown GBS status with risk factors such as preterm labour or prolonged rupture of membranes. Screening too early, such as at 20 weeks, does not reliably predict colonization status at the time of delivery.

• A. Screening at 20 weeks is too early and does not reliably predict colonization status at delivery.
• C. Urine culture at 12 weeks screens for asymptomatic bacteriuria, not GBS colonization status near term, and fever alone is not the standard criterion for prophylaxis.
• D. Blood culture is not used for GBS screening; a vaginal-rectal swab culture is the correct specimen and timing.
• E. Prophylaxis should be given intrapartum to prevent neonatal infection, not withheld until after sepsis has already developed.

For women at average risk of neural tube defects, Canadian guidelines recommend daily folic acid supplementation of 0.4 to 1.0 mg, ideally started at least 2 to 3 months before conception and continued through the first trimester, to reduce the risk of neural tube defects. Higher-dose folic acid, 4 to 5 mg daily, is reserved for women at increased risk, such as those with a personal or family history of a neural tube defect-affected pregnancy, pre-existing diabetes, or use of certain antiepileptic drugs. Dietary folate intake alone is not considered sufficient to achieve the protective serum folate levels needed before conception. Supplementation should begin before conception, not after pregnancy is confirmed, because neural tube closure occurs very early in gestation.

• A. Diet alone does not reliably provide the folate levels shown to reduce neural tube defect risk.
• B. Starting in the second trimester is far too late, since the neural tube closes by around 28 days after conception.
• C. This high dose is reserved for women at increased risk of neural tube defects, not average-risk women.
• D. This dose is too low and started too late; supplementation should begin before conception at 0.4-1.0 mg daily.

Inactivated influenza vaccine is recommended during any trimester of pregnancy because pregnant women are at increased risk of influenza complications. Tdap (tetanus-diphtheria-acellular pertussis) is recommended between 27 and 32 weeks gestation in every pregnancy to maximize transplacental transfer of maternal pertussis antibodies to protect the neonate before the infant series begins. Live attenuated vaccines, including varicella, MMR, and live intranasal influenza vaccine, are contraindicated in pregnancy because of theoretical risk of fetal infection. Non-immune or incompletely immunized patients should receive live vaccines postpartum.

• A. Varicella vaccine is a live attenuated vaccine and is contraindicated during pregnancy; it should be given postpartum.
• B. MMR is a live attenuated vaccine and is contraindicated during pregnancy.
• D. The intranasal influenza vaccine is live attenuated and contraindicated in pregnancy; only the inactivated injectable form should be used.
• E. Live oral typhoid vaccine is contraindicated in pregnancy; the inactivated injectable form could be considered if indicated.

New-onset hypertension (systolic ≥140 mmHg or diastolic ≥90 mmHg) arising after 20 weeks gestation in a woman who was normotensive earlier in pregnancy, without proteinuria or other features of preeclampsia, defines gestational hypertension. Chronic hypertension is diagnosed when elevated blood pressure predates pregnancy or is present before 20 weeks, which does not apply here given her normal first-trimester reading. Preeclampsia requires hypertension plus proteinuria or other evidence of maternal end-organ or uteroplacental dysfunction, which is absent in this patient. Gestational hypertension requires close monitoring because a proportion of cases progress to preeclampsia.

• A. Her blood pressure was normal at 8 weeks, ruling out hypertension predating pregnancy or diagnosed before 20 weeks.
• B. This requires a pre-existing diagnosis of chronic hypertension, which she does not have.
• C. Preeclampsia requires proteinuria or another marker of end-organ dysfunction, both of which are absent here.
• E. White coat hypertension is a clinic-only elevation not confirmed by ambulatory or repeated standardized readings; this diagnosis is not supported by the information given and is not a standard pregnancy classification.

Persistent severe hypertension refractory to treatment together with new cerebral or visual symptoms are severe features of preeclampsia that mandate delivery irrespective of gestational age, because the risk of maternal complications such as eclampsia, stroke, or placental abruption outweighs the benefit of further fetal maturation. Magnesium sulfate for seizure prophylaxis should be started and delivery expedited after maternal stabilization. Expectant management is reserved for preeclampsia without severe features at early gestational ages under close surveillance, which does not apply here.

• B. Adjusting oral antihypertensives and reassessing in a week ignores the urgent indication for delivery.
• C. Discharging a patient with severe preeclampsia features is unsafe and inappropriate.
• D. Expectant management is unsafe once severe features such as refractory severe hypertension and cerebral symptoms are present.
• E. Delaying delivery to give a second steroid course disregards the immediate maternal risk posed by uncontrolled severe hypertension and neurologic symptoms.

Labetalol is a first-line oral antihypertensive in pregnancy, along with nifedipine extended-release and methyldopa, based on established safety and efficacy data in pregnant populations. ACE inhibitors (ramipril) and angiotensin receptor blockers (losartan) are contraindicated throughout pregnancy because of fetal renal dysgenesis, oligohydramnios, and risk of fetal and neonatal death, particularly with second- and third-trimester exposure. Atenolol is avoided because of associations with fetal growth restriction, and thiazide diuretics are not recommended as first-line therapy in pregnancy.

• B. ACE inhibitors are contraindicated in pregnancy because of fetopathy including renal failure and oligohydramnios.
• C. Atenolol is associated with fetal growth restriction and is not a preferred agent in pregnancy.
• D. Angiotensin receptor blockers carry the same fetal risks as ACE inhibitors and are contraindicated in pregnancy.
• E. Thiazide diuretics are not recommended as first-line antihypertensive therapy in pregnancy.

Absent deep tendon reflexes, respiratory depression, and decreased level of consciousness are signs of magnesium toxicity, which occurs when serum magnesium levels rise above the therapeutic range and impair neuromuscular transmission. Calcium gluconate is the specific antidote because it competitively antagonizes magnesium at the neuromuscular junction and should be given immediately along with stopping the infusion. Monitoring for toxicity includes serial assessment of respiratory rate, oxygen saturation, deep tendon reflexes, and urine output, since magnesium is renally excreted and toxicity risk increases with renal impairment.

• B. Continuing the infusion without intervention risks progression to respiratory arrest and cardiac toxicity.
• C. Oral magnesium is not used for seizure prophylaxis in preeclampsia and would not address the current toxicity.
• D. Diazepam is not indicated here; the findings reflect magnesium toxicity, not a seizure, and benzodiazepines would compound respiratory depression.
• E. Increasing the infusion rate would worsen magnesium toxicity and could cause respiratory arrest or cardiac arrest.

Placenta previa classically presents with painless, bright red vaginal bleeding, a soft non-tender uterus, and a reassuring fetal heart tracing, as seen here. Placental abruption instead typically causes painful bleeding with uterine tenderness or hypertonus and often fetal heart rate abnormalities, reflecting bleeding into the myometrium rather than externally. The absence of pain and uterine tenderness in this case argues strongly against abruption. Confirmation is by ultrasound showing the placental edge covering or near the internal cervical os.

• A. Abruption presents with painful bleeding and a tender, often hypertonic uterus, not seen here.
• C. Uterine rupture causes severe pain, loss of fetal station, and maternal hemodynamic instability, usually in a scarred uterus.
• D. Vasa previa bleeding follows membrane rupture and causes fetal heart rate abnormalities from fetal blood loss, not maternal bleeding alone.
• E. Preterm labour presents with regular contractions and cervical change, not isolated painless bleeding.

In any patient with painless vaginal bleeding in the second half of pregnancy, placenta previa must be excluded before any digital examination is performed, because palpating or disrupting a previa can provoke catastrophic hemorrhage. Transvaginal ultrasound is safe and accurate for localizing the placenta relative to the internal cervical os and is the investigation of choice. Once previa is excluded, a digital exam can be performed if clinically indicated. Management decisions should follow once the diagnosis is confirmed.

• A. Digital examination is contraindicated until placenta previa has been excluded, as it may provoke severe hemorrhage.
• C. Emergency cesarean is not warranted in a stable patient with reassuring fetal status and resolved bleeding before imaging.
• D. Oxytocin is not indicated and could worsen bleeding if a previa is present.
• E. Speculum and swabs do not localize the placenta and are not the priority when previa is suspected.

Velamentous cord insertion and a bilobed (or succenturiate-lobed) placenta are major risk factors for vasa previa, in which fetal vessels run unsupported through the membranes over or near the cervix. When the membranes rupture, these vessels can tear, causing fetal hemorrhage that rapidly leads to fetal bradycardia and can be fatal within minutes if delivery is not expedited. The combination of membrane rupture, vaginal bleeding, and acute severe fetal heart rate decompensation in a patient with known risk factors is the classic presentation of vasa previa. Immediate emergency cesarean delivery is required.

• A. Nuchal cord compression does not typically cause vaginal bleeding and is unrelated to velamentous insertion.
• C. Chorioamnionitis causes fetal tachycardia, not bradycardia, and does not explain the bleeding pattern described.
• D. Abruption causes painful bleeding with uterine hypertonus, which is not described here, and the known cord insertion anomaly points to vasa previa.
• E. Maternal hypotension would not explain the associated vaginal bleeding in this setting.

When beta-hCG is below the discriminatory zone (typically under 1500-2000 IU/L) and ultrasound shows no intrauterine or adnexal sac, the pregnancy location is indeterminate and could represent a very early normal intrauterine pregnancy, an early pregnancy loss, or an ectopic pregnancy. The appropriate next step is to repeat beta-hCG in 48 hours: a rise of at least 53% is consistent with a normal intrauterine pregnancy, a slower rise or plateau raises concern for ectopic pregnancy, and a falling level suggests a failing pregnancy. This serial trend guides further investigation and timing of repeat ultrasound, and avoids unnecessary intervention in a hemodynamically stable patient.

• A. Repeating ultrasound in 2 weeks is too long a delay in a patient who needs closer monitoring for possible ectopic pregnancy.
• C. Methotrexate should not be given before confirming an ectopic pregnancy, as it could harm a viable intrauterine pregnancy.
• D. Progesterone level is less useful than the beta-hCG trend for distinguishing these diagnoses and is not routinely used in current Canadian practice.
• E. Curettage is invasive and inappropriate before the pregnancy location is established, risking termination of a viable intrauterine pregnancy.

Methotrexate is appropriate for a hemodynamically stable patient with an unruptured ectopic pregnancy, a mass under about 3.5 to 4 cm, no fetal cardiac activity, and beta-hCG levels generally below 5000 IU/L, provided there are no contraindications such as renal or hepatic impairment, immunodeficiency, breastfeeding, or a known sensitivity to methotrexate. This patient meets all of these criteria, making medical management with methotrexate the preferred first-line option over surgery. It works by inhibiting trophoblastic cell division, allowing the ectopic tissue to be resorbed while avoiding surgical risks and preserving tubal fertility.

• A. Surgery is reserved for ruptured ectopic pregnancy, hemodynamic instability, contraindications to methotrexate, or failed medical therapy.
• B. Misoprostol is used for uterine evacuation in intrauterine pregnancy loss, not for treating ectopic pregnancy.
• C. Laparotomy is more invasive than necessary when the patient is stable and meets criteria for medical management.
• D. Expectant management is not standard once an ectopic pregnancy is confirmed with a rising beta-hCG and visible mass, given the risk of rupture.

Antenatal corticosteroids are recommended for women at risk of preterm birth between 24 and 34 weeks gestation (and in select cases up to 36 weeks 6 days) to accelerate fetal lung maturation and reduce the risk of respiratory distress syndrome, intraventricular hemorrhage, and neonatal mortality. Betamethasone, given as two intramuscular doses 24 hours apart, is the preferred agent in Canadian and SOGC guidelines because of its well-established efficacy and safety profile in large trials. This patient is in preterm labour at 29 weeks, squarely within the recommended window, making betamethasone the appropriate choice. Dexamethasone phosphate is an alternative in some protocols, but betamethasone remains the standard first-line option.

• A. Inhaled budesonide acts locally on the respiratory tract and provides no benefit for fetal lung maturation when inhaled by the mother.
• B. Intravenous hydrocortisone is not the standard agent for antenatal fetal lung maturation.
• D. Oral prednisone does not cross the placenta effectively and is not used for fetal lung maturation.
• E. Dexamethasone acetate is a long-acting depot formulation not used for this indication; dexamethasone phosphate is the alternative agent when used.

Preterm premature rupture of membranes is diagnosed clinically by pooling of fluid, a positive nitrazine test, and history, as seen here. In the absence of infection, labour, or fetal compromise, initial management before 34 weeks includes antenatal corticosteroids to promote fetal lung maturity and latency antibiotics (commonly a combination such as erythromycin or azithromycin with ampicillin) to prolong the latency period and reduce maternal and neonatal infection risk. Expectant management is preferred over immediate delivery at this gestational age unless there are signs of chorioamnionitis, abruption, or fetal distress. Digital examination should be avoided to reduce the risk of introducing infection.

• A. Cesarean section is not indicated based on rupture of membranes alone without an obstetric indication such as malpresentation or fetal distress.
• C. Tocolysis is not first-line in PPROM and discharge home is inappropriate given the risk of infection and cord prolapse requiring inpatient monitoring.
• D. Digital examination increases the risk of ascending infection and should be avoided in favour of sterile speculum assessment.
• E. Immediate induction is not indicated in a stable patient at 32 weeks without infection or fetal distress; expectant management with steroids and antibiotics is preferred.

In placental insufficiency, chronic fetal hypoxia triggers a brain-sparing reflex that redistributes cardiac output to the brain, heart, and adrenal glands at the expense of the kidneys and gut. Reduced renal perfusion decreases fetal urine output, which is the main contributor to amniotic fluid after mid-gestation, producing oligohydramnios. This is distinct from structural causes such as renal agenesis or obstructive uropathy, which would show abnormal kidney anatomy on ultrasound. The absent end-diastolic umbilical artery flow in this case confirms significant placental insufficiency as the underlying driver.

• A. Posterior urethral valves cause a distended bladder and hydronephrosis, which are not described here.
• B. A swallowing defect from aneuploidy typically causes polyhydramnios, not oligohydramnios.
• C. Ruptured membranes would show a history of fluid leakage and is not suggested by the clinical picture, which instead points to Doppler evidence of placental insufficiency.
• D. Renal agenesis would show absent or dysplastic kidneys on ultrasound, not normal-appearing kidneys as described.

Late decelerations with decreased variability suggest uteroplacental insufficiency, often worsened by excessive uterine activity from oxytocin and by supine positioning causing aortocaval compression. The first step in intrauterine resuscitation is to stop the oxytocin to reduce contraction frequency and reposition the patient to the left lateral position to improve uteroplacental blood flow. Other resuscitation measures such as intravenous fluid bolus and oxygen administration may follow, with escalation to delivery reserved for tracings that remain abnormal despite these measures. Immediate caesarean section without first attempting conservative resuscitative measures is not appropriate unless the tracing is abnormal and resuscitation fails.

• A. A fetal scalp electrode improves tracing clarity but does not address the underlying cause of the decelerations and delays resuscitative action.
• B. Terbutaline may be used as a tocolytic in some protocols, but continuing oxytocin at the same rate is contraindicated when it is contributing to uteroplacental insufficiency.
• D. Emergency caesarean section is premature before attempting standard intrauterine resuscitation measures for a tracing that may improve.
• E. A bolus of oxytocin would worsen uterine activity and further compromise placental perfusion.

Arrest of the active phase of labour is diagnosed when there is no cervical change for at least 4 hours despite adequate uterine contractions (generally defined as 200 Montevideo units or more), or no change for 6 hours with inadequate contractions, in a woman who has reached the active phase (typically 6 cm or more dilation with ruptured membranes). This patient meets criteria with documented adequate contraction strength and no cervical change over 4 hours. Protracted labour refers to a slower-than-normal rate of progress rather than complete cessation, and is a different diagnostic category used before arrest criteria are met.

• A. Protracted active phase refers to a slow but ongoing rate of dilation, not a complete 4-hour cessation as described here.
• C. The patient is already in the active phase at 6 cm, so prolonged latent phase does not apply.
• D. Normal active phase labour would show progressive cervical dilation, which is absent here.
• E. Secondary arrest of descent refers specifically to cessation of fetal descent after the active phase has begun with full dilation reached, not to lack of cervical dilation change.

Operative vaginal delivery is indicated when there is a non-reassuring fetal heart rate pattern in the second stage of labour with a fetus at a low station (+3, engaged, occiput anterior) and a fully dilated cervix, since these criteria allow for rapid, safe vaginal delivery rather than a more time-consuming and higher-risk caesarean section. Prerequisites for a safe operative vaginal delivery include a known fetal position, adequate pelvis, empty bladder, and an experienced operator, all of which are satisfied here. Continuing to await spontaneous delivery is inappropriate given the abnormal fetal heart tracing, and caesarean section is unnecessary when conditions favour a low, safe instrumental delivery.

• B. Oxytocin augmentation does not address the urgency created by the abnormal fetal heart tracing and does not expedite delivery as effectively as instrumental delivery.
• C. Fundal pressure is not a recommended technique for assisting fetal descent and carries risk of uterine or fetal injury without added benefit.
• D. Caesarean section is a more invasive and slower option when the fetal head is low, engaged, and well-positioned, making operative vaginal delivery the safer and faster choice.
• E. Continuing to wait is inappropriate given the abnormal fetal heart rate tracing indicating possible fetal compromise that requires expedited delivery.

Breech presentation at term combined with a prior Cesarean section is an indication for planned repeat Cesarean section, as the combination of malpresentation and a uterine scar substantially increases risk during a trial of labour. Vaginal breech delivery is only considered in carefully selected candidates with a cephalic-compatible pelvis and no other risk factors, and a prior uterine scar is a relative contraindication in most protocols. Repeating external cephalic version in labour is not recommended once labour has started, and internal podalic version is an obsolete and dangerous technique. SOGC guidelines support individualized counselling, but with a scarred uterus and persistent breech at term, Cesarean delivery is the safest option.

• A. External cephalic version is not performed once the patient is in active labour.
• B. A trial of labour with a term breech on a scarred uterus carries unacceptably high combined risk of cord prolapse, head entrapment, and uterine rupture.
• C. Internal podalic version is an obsolete technique associated with high fetal and maternal morbidity.
• D. Assisted vaginal breech delivery is reserved for carefully selected unscarred uteri without other risk factors.

For women with one previous low transverse Cesarean section attempting a trial of labour after Cesarean, the risk of uterine rupture is approximately 0.5%, and SOGC guidelines support offering a trial of labour to appropriate candidates after informed discussion of risks and benefits. Oxytocin augmentation does not eliminate rupture risk and may modestly increase it, so its use requires careful monitoring rather than reassurance. Classical (vertical) incisions carry a much higher rupture risk, around 4 to 9%, and are a contraindication to trial of labour, but low transverse incisions are not. Respecting patient autonomy requires accurate numeric risk counselling so the patient can make an informed shared decision about mode of delivery.

• A. Rupture can occur with low transverse incisions as well, although at much lower rates than with classical incisions.
• B. Oxytocin does not eliminate rupture risk and should be used cautiously with close monitoring during VBAC attempts.
• D. This figure greatly overstates the rupture risk for a single prior low transverse incision.
• E. A single prior low transverse Cesarean section is not a contraindication to a trial of labour.

In a patient with an unfavourable cervix, defined by a low Bishop score, cervical ripening with a prostaglandin agent such as vaginal dinoprostone is the appropriate first step before oxytocin augmentation, since oxytocin is far less effective and carries higher risk of failed induction when the cervix is unripe. Oxytocin alone or artificial rupture of membranes are better suited to patients with a favourable cervix, and attempting either on a closed, firm cervix increases the risk of prolonged labour and failed induction. Oxytocin boluses are never used because they risk uterine tachysystole and fetal compromise; oxytocin is always titrated as a continuous infusion. Membrane stripping alone is insufficient for a post-term pregnancy requiring definitive induction and is not a substitute for formal cervical ripening.

• A. Artificial rupture of membranes on an unfavourable, closed cervix is difficult, risky, and ineffective.
• B. Oxytocin is far less effective when the cervix is unfavourable and should follow cervical ripening.
• D. Oxytocin is given as a titrated continuous infusion; bolus dosing risks uterine tachysystole and fetal compromise.
• E. Membrane stripping alone is inadequate for definitive induction in a post-term pregnancy with an unfavourable cervix.

Umbilical cord prolapse is an obstetric emergency caused by cord compression between the fetal presenting part and the pelvis, leading to fetal hypoxia. The immediate priority is to relieve compression by manually elevating the presenting part off the cord while positioning the mother in Trendelenburg or knee-chest position, followed by urgent preparation for emergency Cesarean section. Tocolytics such as terbutaline may be used as an adjunct to reduce contractions while preparing for delivery, but they are not the first action and do not replace manual decompression. Oxytocin is contraindicated because it would worsen contractions and compression, and amniotomy or scalp electrode placement are irrelevant and would delay emergency management.

• A. The membranes have already ruptured; amniotomy is irrelevant and delays urgent management of cord compression.
• C. Terbutaline may be used as an adjunct but manual elevation of the presenting part must happen immediately, not after a delay.
• D. Confirming the fetal heart tracing is irrelevant; the diagnosis is already clear and action must be immediate.
• E. Oxytocin would worsen uterine contractions and increase cord compression, endangering the fetus further.

A soft, poorly contracted, boggy uterus with ongoing bleeding after a complete placenta and no visible lacerations points to uterine atony, the most common cause of postpartum hemorrhage under the 4 T's framework (tone, tissue, trauma, thrombin). The initial step in managing atony is bimanual uterine massage and compression to stimulate contraction, performed simultaneously with uterotonic drug administration and resuscitation. Laparotomy is reserved for cases refractory to medical management and massage. Since the placenta is complete and no laceration is seen, manual removal of tissue or surgical repair of trauma are not indicated. Fresh frozen plasma is used for coagulopathy, not as an initial step when the cause is clearly atony.

• A. The placenta is described as grossly complete, so retained tissue is not the most likely cause.
• C. Fresh frozen plasma addresses coagulopathy, which has not been demonstrated here; the clinical picture indicates atony.
• D. Laparotomy is reserved for hemorrhage refractory to initial medical and mechanical measures, not the first step.
• E. No cervical laceration was identified on examination, making this an incorrect presumed diagnosis.

Postpartum endometritis is a clinical diagnosis based on fever, uterine tenderness, and foul-smelling lochia in the days following delivery, and it is more common after Cesarean section, especially with risk factors such as prolonged rupture of membranes. The intact, non-erythematous incision argues against a surgical site infection, and the normal urinalysis excludes a urinary tract infection as the fever source. Retained products of conception can predispose to infection but would typically be accompanied by ultrasound findings of retained tissue, which is not mentioned here, and the clinical triad described is classic for endometritis itself. Septic pelvic thrombophlebitis is a diagnosis of exclusion typically considered when fever persists despite appropriate antibiotics for endometritis, not an initial diagnosis.

• A. This diagnosis is considered when fever persists despite antibiotic treatment for endometritis, not as an initial presentation.
• B. The incision is described as clean, dry, and intact with no erythema or discharge, making wound infection unlikely.
• D. Urinalysis is unremarkable, making a urinary source for the fever unlikely.
• E. No evidence of retained tissue is provided, and the clinical triad fits infection of the endometrium directly.

Sertraline has the largest body of safety data in lactation, with very low and often undetectable levels in infant serum, and is considered the SSRI of choice for breastfeeding mothers. Fluoxetine has a long half-life and active metabolite that can accumulate in the infant, making it less preferred than sertraline. Doxepin is specifically contraindicated during lactation due to case reports of infant respiratory depression. Lithium and clozapine both pass into breast milk in significant amounts and require close infant monitoring or are generally avoided due to toxicity risk.

• A. Lithium is excreted in breast milk at high levels and carries risk of infant toxicity, requiring careful monitoring if used at all.
• C. Doxepin is contraindicated in breastfeeding due to reports of infant sedation and respiratory depression.
• D. Clozapine is generally avoided during breastfeeding due to risk of agranulocytosis and sedation in the infant.
• E. Fluoxetine's long half-life and active metabolite can accumulate in breastfed infants, making it a second-line choice.

The lactational amenorrhea method (LAM) is greater than 98% effective when three criteria are all met: the woman is less than 6 months postpartum, she remains amenorrheic, and she is exclusively or near-exclusively breastfeeding (including night feeds) without significant supplementation. Once any of these criteria is no longer met, effectiveness drops substantially and a backup method should be started. This makes LAM a useful but time-limited and condition-dependent method of contraception in the early postpartum period.

• A. Return of menses signals loss of contraceptive protection from LAM, so it does not need to occur first; its absence is actually a requirement.
• C. LAM is in fact highly effective in the early postpartum period when strict criteria are met, so dismissing it entirely is incorrect.
• D. Effectiveness declines significantly after 6 months postpartum even with continued breastfeeding, so this timeframe is incorrect.
• E. Supplementation with formula reduces breastfeeding frequency and intensity, which decreases rather than enables LAM effectiveness.

This patient has multiple risk factors for postpartum venous thromboembolism: emergency cesarean section, obesity (BMI greater than 30 kg/m²), and varicose veins, placing her in a higher-risk category according to SOGC guidelines. Combined pharmacologic prophylaxis with low-molecular-weight heparin and early mobilization is recommended when multiple risk factors are present after cesarean delivery. Mechanical prophylaxis alone is reserved for patients with contraindications to anticoagulation or lower-risk profiles. Aspirin is not an evidence-based option for postpartum VTE prophylaxis, and warfarin is not used acutely because of its delayed onset and the need for bridging, making it impractical and unnecessary here.

• A. Mechanical prophylaxis alone is insufficient given her multiple risk factors; pharmacologic prophylaxis is indicated in addition.
• B. Warfarin has delayed onset of action and is not appropriate for immediate postoperative thromboprophylaxis.
• C. Aspirin is not a standard or evidence-based agent for postpartum VTE prophylaxis.
• D. This patient has multiple risk factors (cesarean, obesity, varicose veins) that elevate her risk, so no prophylaxis would be inadequate.

This presentation, regular heavy menstrual bleeding with an irregularly enlarged, bulky, non-tender uterus, is classic for uterine leiomyomas (fibroids), the 'M' in the PALM-COEIN classification of structural causes of abnormal uterine bleeding. Transvaginal ultrasound is the first-line imaging investigation to assess uterine structure, identify fibroids, and evaluate endometrial thickness. Endometrial biopsy is reserved for women with risk factors for endometrial hyperplasia or cancer, such as irregular bleeding patterns or age over 45 with risk factors, which this patient does not clearly have given her regular cycles. CA-125 and laparoscopy are not first-line tests for heavy menstrual bleeding, and thyroid dysfunction would not typically cause a bulky, irregular uterus on examination.

• B. Thyroid dysfunction can cause abnormal bleeding but does not explain an irregularly enlarged, bulky uterus on examination.
• C. Endometrial biopsy is not first-line here since the regular cyclic pattern and exam findings point to a structural cause best evaluated with imaging first.
• D. Diagnostic laparoscopy is invasive and not a first-line investigation for suspected fibroids, which can be visualized non-invasively.
• E. CA-125 is a tumour marker for ovarian malignancy and is not indicated as an initial test for heavy menstrual bleeding with a bulky uterus.

The combination of progressively worsening cyclic pelvic pain starting before menses, deep dyspareunia, dyschezia during menstruation, and examination findings of posterior fornix nodularity with a fixed retroverted uterus is classic for endometriosis, a form of secondary dysmenorrhea caused by endometrial tissue implants outside the uterine cavity, often involving the uterosacral ligaments or rectovaginal septum. Primary dysmenorrhea typically begins at menarche or shortly after, is not progressive, and lacks these examination findings. Adenomyosis classically presents with a diffusely enlarged, tender, boggy uterus rather than nodularity and fixation. Pelvic inflammatory disease presents with signs of infection such as fever and cervical motion tenderness, and fibroids present with an irregularly enlarged uterus rather than posterior fornix nodularity.

• A. Adenomyosis typically causes a diffusely enlarged, boggy, tender uterus rather than posterior nodularity and fixation.
• B. Primary dysmenorrhea begins near menarche and does not worsen progressively or cause posterior fornix nodularity and dyspareunia.
• C. Pelvic inflammatory disease would present with signs of infection such as fever, purulent discharge, or cervical motion tenderness, which are absent here.
• D. Uterine fibroids typically cause an irregularly enlarged uterus and heavy bleeding rather than posterior fornix nodularity and dyspareunia.

The levonorgestrel intrauterine system is highly effective, long-acting, and does not require daily adherence, directly addressing this patient's history of inconsistent medication adherence. Importantly, fertility returns promptly after removal, which an intrauterine device allows at any time, matching her desire for quick reversibility. Combined oral contraceptive pills and progestin-only pills require daily adherence, which is a poor fit given her history. Depot medroxyprogesterone acetate is long-acting but can delay return to fertility for several months after the last injection, and condoms, while user-independent in dosing schedule, have higher typical-use failure rates and do not match her request for high effectiveness.

• A. Progestin-only pills require strict daily timing and are a poor fit for someone with adherence difficulties.
• B. Depot medroxyprogesterone acetate can delay return of fertility for several months after discontinuation, conflicting with her wish for quick reversibility.
• C. Male condoms have a higher typical-use failure rate than long-acting reversible methods and do not meet her request for high effectiveness.
• E. Combined oral contraceptive pills require daily adherence, which conflicts with her history of inconsistent medication-taking.

This patient meets Rotterdam criteria for PCOS with two of three features: oligo-ovulation (cycles >35 days), clinical hyperandrogenism (hirsutism), and polycystic ovarian morphology on ultrasound, with other causes of hyperandrogenism excluded. For women with PCOS seeking pregnancy, letrozole, an aromatase inhibitor, is recommended as first-line ovulation induction agent because it achieves higher live birth rates than clomiphene citrate, particularly in obese women with PCOS. It works by transiently lowering estrogen, which reduces negative feedback on the hypothalamic-pituitary axis and increases FSH secretion.

• A. Clomiphene citrate was historically first-line but current evidence and guidelines favor letrozole for superior ovulation and live birth rates in PCOS.
• B. Combined oral contraceptives suppress ovulation and are used for cycle regulation or hyperandrogenism when pregnancy is not desired, not for a patient trying to conceive.
• C. Gonadotropins are reserved for cases resistant to oral ovulation induction agents due to higher cost and multiple pregnancy risk.
• D. Metformin improves insulin sensitivity but is less effective than letrozole for ovulation induction when pregnancy is the immediate goal.

The standard initial infertility workup for a couple includes a semen analysis for the male partner and confirmation of ovulation plus assessment of tubal patency for the female partner, with semen analysis typically obtained first because it is noninvasive, inexpensive, and quickly identifies a male factor present in roughly 40-50% of infertile couples. Ovulatory cycles are already supported by this patient's regular 28-day cycle history. Semen analysis should precede invasive female investigations such as tubal imaging, which carry procedural risk and cost and are unnecessary if a severe male factor is found first.

• A. Hysterosalpingogram evaluates tubal patency and uterine cavity but is invasive and should follow semen analysis in the initial workup sequence.
• B. Laparoscopy is a second-line invasive investigation reserved for suspected pelvic pathology such as endometriosis, not part of the initial workup.
• D. Endometrial biopsy to assess luteal phase is no longer routinely recommended and is not part of first-line infertility investigation.
• E. Ovarian reserve testing such as the clomiphene challenge test is not indicated here given her regular cycles and is not the first step in a couple's workup.

This patient has reached menopause, defined as 12 consecutive months of amenorrhea, and her vasomotor symptoms warrant treatment. However, a personal history of hormone receptor-positive breast cancer is an absolute contraindication to systemic estrogen-containing hormone therapy because estrogen can stimulate occult residual malignant cells and promote recurrence. For this patient, non-hormonal options such as SSRIs, SNRIs, gabapentin, or cognitive behavioural therapy should be offered for vasomotor symptom management instead. The receptor status being positive strengthens the contraindication rather than making therapy safe.

• A. A mammogram does not address the fundamental contraindication of hormone-sensitive malignancy history.
• B. Estrogen receptor-positive status means her tumor cells can respond to estrogen stimulation, which increases rather than eliminates recurrence risk.
• C. The 'window of opportunity' concept applies to women without contraindications; it does not override an absolute contraindication like hormone-sensitive breast cancer.
• D. Estrogen antagonizes the therapeutic action of tamoxifen and combining them is inappropriate and unsafe.

Any postmenopausal bleeding requires investigation to exclude endometrial carcinoma, and transvaginal ultrasound measurement of endometrial thickness is an appropriate and widely accepted initial, noninvasive triage tool. An endometrial thickness of 4 mm or less in a postmenopausal woman has a very low likelihood of malignancy and can allow conservative follow-up, whereas thickness greater than 4 mm warrants endometrial sampling. This stepwise approach avoids unnecessary invasive procedures in low-risk women while ensuring prompt biopsy when ultrasound findings are concerning.

• A. MRI is not used as a first-line screening test for postmenopausal bleeding and is reserved for staging confirmed malignancy.
• C. Dilation and curettage is an invasive procedure requiring anesthesia and is not first-line initial investigation.
• D. Hysteroscopy is more invasive and reserved for cases with abnormal ultrasound findings, focal lesions, or non-diagnostic biopsy.
• E. Endometrial biopsy is appropriate but is typically performed after ultrasound stratifies risk, or if bleeding is recurrent or risk factors are high; here ultrasound is the accepted initial step.

This patient's symptoms of leakage with increased intra-abdominal pressure (coughing, sneezing, lifting), without urgency, are characteristic of stress urinary incontinence caused by urethral sphincter or pelvic floor weakness, often related to prior vaginal deliveries. Pelvic floor muscle training, such as supervised Kegel exercises, is the recommended first-line treatment for stress incontinence because it strengthens the pelvic floor musculature and improves urethral support with minimal risk. Surgical options are reserved for cases that fail an adequate trial of conservative therapy.

• B. Mirabegron is a beta-3 agonist used for overactive bladder/urge incontinence, not appropriate for pure stress incontinence.
• C. Topical vaginal estrogen may help atrophy-related urinary symptoms but is not first-line treatment for stress incontinence from pelvic floor weakness.
• D. Mid-urethral sling surgery is effective for stress incontinence but is reserved for patients who fail conservative measures like pelvic floor training.
• E. Oxybutynin is an anticholinergic used for urge incontinence or overactive bladder, not for stress incontinence.

The Canadian Task Force on Preventive Health Care recommends initiating routine cervical cancer screening with cytology at age 25, regardless of age at first intercourse, because cervical cancer is rare before age 25 and screening at younger ages leads to overdiagnosis and overtreatment of lesions that would otherwise regress spontaneously. Screening is then recommended every 3 years from age 25 to 69 for average-risk women. This patient, currently 24, should begin screening once she reaches the recommended starting age.

• A. Age 21 was a previous threshold in some older guidelines but is not the current CTFPC recommendation.
• B. Screening intervals are based on age, not solely on reported new sexual partners.
• D. Starting at age 24 is earlier than the CTFPC-recommended start age of 25 for average-risk women.
• E. HPV co-testing and age 30 initiation reflect different program models, not the current CTFPC cytology-based recommendation of starting at 25.

A result of high-grade squamous intraepithelial lesion on Pap testing indicates a significant risk of underlying cervical intraepithelial neoplasia grade 2 or 3, and current guidelines recommend direct referral for colposcopy with biopsy rather than repeat cytology. Colposcopy allows visual examination of the cervix with acetic acid application and directed biopsy of abnormal areas to confirm the degree of dysplasia and guide treatment. Repeat cytology or HPV testing alone would delay diagnosis and risk progression to invasive cancer, while excisional treatment should not be performed empirically without histologic confirmation.

• A. HPV testing alone does not characterize the degree of cytologic abnormality already identified and does not replace the need for colposcopic assessment.
• C. Repeating cytology in 6 months is appropriate for lower-risk results like ASCUS in some protocols, not for HSIL which requires prompt colposcopic evaluation.
• D. A 12-month repeat delays necessary evaluation of a high-grade lesion and risks disease progression.
• E. Performing an excisional procedure without histologic confirmation via colposcopy and biopsy is not standard practice and risks overtreatment.

Canadian guidelines (NACI, provincial school immunization programs) recommend routine HPV vaccination of all adolescents, both sexes, at age 9-12 years, ideally before the onset of sexual activity, to maximize immunogenicity and prevent exposure before infection can occur. Vaccinating prior to sexual debut gives the greatest protection against persistent high-risk HPV infection that leads to cervical, anal, and oropharyngeal cancers. The vaccine is approved and beneficial for both sexes, not girls alone. Catch-up programs exist for older unvaccinated individuals, but these are not the primary target population.

• A. Restricting to girls ignores male-mediated transmission and HPV-related cancers in men; current programs include boys.
• C. Vaccination at this age still provides benefit but is less effective than pre-exposure vaccination in younger adolescents.
• D. This age range is for cervical screening, not the target population for primary HPV vaccination.
• E. Limiting to a specific sexual orientation group ignores universal recommendations and is not how population programs are designed.

Any postmenopausal bleeding, even a single light episode, must be investigated to exclude endometrial cancer, and this patient has multiple risk factors: obesity, diabetes, nulliparity, and unopposed estrogen exposure from peripheral conversion in adipose tissue. Transvaginal ultrasound to measure endometrial thickness is the recommended first-line investigation; a thickness greater than 4-5 mm or a thickened/heterogeneous endometrium warrants endometrial biopsy. This stepwise, non-invasive approach avoids unnecessary biopsies in women with a thin endometrial lining while still identifying those who need tissue sampling.

• A. Hormonal therapy would mask bleeding and delay diagnosis of a potential malignancy; it is not a diagnostic step.
• C. CT is not the first-line test for evaluating the endometrium and has poor sensitivity for early endometrial pathology.
• D. Postmenopausal bleeding is never physiologic and requires investigation, not reassurance.
• E. The Pap smear screens for cervical, not endometrial, pathology and is not sensitive for endometrial cancer.

A simple unilocular cyst with thin smooth walls, no septations, no solid or papillary components, and no abnormal vascularity on Doppler, combined with a normal CA-125, has features consistent with a benign functional or simple ovarian cyst. Such findings carry a very low risk of malignancy and can be managed conservatively with interval ultrasound to confirm resolution or stability, following SOGC guidance on adnexal mass management. Features that raise concern for malignancy include solid components, papillary projections, thick irregular septations, ascites, and elevated tumour markers, none of which are present here.

• A. There are no symptoms (acute pain) or imaging findings (free fluid, asymmetric enlargement, absent flow) described that suggest torsion.
• C. The described features (thin walls, no septations, no solid parts, normal CA-125) are reassuring, not suspicious for malignancy.
• D. Immediate surgery is not indicated for a mass with benign sonographic features.
• E. A mature cystic teratoma typically shows a complex appearance with echogenic foci or fat-fluid levels, not a simple thin-walled unilocular cyst.

Women with pathogenic BRCA1 mutations have a lifetime ovarian cancer risk of approximately 40-50%, and risk-reducing bilateral salpingo-oophorectomy (RRSO), typically recommended between ages 35 and 40 years once childbearing is complete, is the most effective intervention and reduces ovarian cancer risk by over 80-90%. Screening with ultrasound and CA-125 has not been shown to improve early detection or survival and is not a substitute for surgery. Counselling must also address the ethical dimension of informed, autonomous decision-making, including discussion of surgical menopause, hormone replacement therapy considerations, and the impact on fertility and quality of life.

• A. BRCA1 mutations substantially increase both breast and ovarian cancer risk; reassurance is inappropriate and could cause harm.
• B. Hysterectomy alone does not remove the ovaries and fallopian tubes, the primary source of BRCA-associated gynecologic cancer risk.
• C. Oral contraceptives modestly reduce ovarian cancer risk but are not sufficient alone for a high-risk BRCA1 carrier and carry their own risks.
• D. Screening alone has not been shown to reduce mortality in BRCA carriers and is not a recommended substitute for risk-reducing surgery.

This presentation meets the minimum clinical criteria for pelvic inflammatory disease (PID): lower abdominal pain with cervical motion, uterine, or adnexal tenderness in a sexually active woman with no other identified cause, and treatment should begin empirically without waiting for microbiologic confirmation. The standard outpatient regimen covers Neisseria gonorrhoeae and Chlamydia trachomatis with ceftriaxone and doxycycline, with metronidazole often added to cover anaerobes, particularly if bacterial vaginosis or instrumentation is suspected. Early empiric treatment prevents long-term sequelae such as tubal factor infertility, ectopic pregnancy, and chronic pelvic pain.

• A. Vancomycin and piperacillin-tazobactam are reserved for severe or hospital-acquired infections, not first-line empiric outpatient PID treatment.
• B. Fluconazole treats fungal infections such as candidiasis, not the bacterial pathogens responsible for PID.
• D. A single dose of azithromycin alone does not reliably cover gonococcal infection or provide adequate anaerobic coverage.
• E. Metronidazole alone does not adequately cover gonorrhea or chlamydia, the key pathogens in PID.

This presentation is classic for bacterial vaginosis: a thin, grey, homogeneous discharge with a fishy odour (worse after intercourse due to alkaline semen), elevated vaginal pH greater than 4.5, and clue cells (epithelial cells coated with bacteria) on wet mount, fulfilling Amsel criteria. First-line treatment is oral metronidazole, which targets the anaerobic overgrowth (notably Gardnerella vaginalis) responsible for the shift in vaginal flora. Unlike candidiasis, bacterial vaginosis is not typically associated with itching or vulvar erythema, and unlike trichomoniasis it does not usually cause a frothy discharge or strawberry cervix.

• A. Clotrimazole is an antifungal for candidiasis and would not address the anaerobic bacterial overgrowth described here.
• B. Clindamycin cream can treat bacterial vaginosis, but this option incorrectly labels it as treatment for candidiasis, making it inconsistent with the diagnosis.
• C. Azithromycin is used for chlamydial infection, not bacterial vaginosis, and does not match this clinical picture.
• E. Fluconazole treats candidiasis, which classically presents with thick, white, curdy discharge and itching, not this presentation.

This patient has a tubo-ovarian abscess with systemic toxicity (fever, tachycardia), a large complex mass greater than 7 cm, and inability to tolerate oral intake, all of which are indications for hospital admission and initiation of intravenous broad-spectrum antibiotics rather than outpatient oral therapy. Most tubo-ovarian abscesses respond to IV antibiotics (such as cefoxitin or clindamycin plus gentamicin-based regimens) within 48 to 72 hours; surgical or percutaneous drainage is reserved for cases that fail to improve or that rupture. Outpatient management is appropriate for uncomplicated PID without abscess, toxicity, or intolerance of oral intake.

• A. Most tubo-ovarian abscesses are managed initially with IV antibiotics; surgery is reserved for failure of medical therapy or rupture, not as a first step.
• B. Brief observation and discharge is inappropriate given systemic toxicity, a large abscess, and intolerance of oral intake; admission is indicated.
• D. Drainage without antibiotics does not address the underlying infection and antibiotics are required regardless of drainage.
• E. Oral outpatient therapy is inadequate given the abscess, systemic toxicity, and inability to tolerate oral intake; admission for IV therapy is required.

In Canada, there is no legal mandate for physicians to report intimate partner violence involving competent adults to police, unlike the mandatory reporting required for suspected child abuse or neglect. The physician's role is to respect patient autonomy, provide a supportive, non-judgmental response, document the disclosure accurately, and offer resources such as shelters, counselling services, and a safety plan, while reassessing risk at future visits. Overriding her explicit wishes by reporting without consent could endanger her safety, damage trust, and is not legally required in this scenario.

• A. Informing the partner violates confidentiality and could place the patient at serious risk of further harm.
• B. There is no legal requirement in Canada for mandatory police reporting of intimate partner violence involving a competent adult patient without her consent.
• C. Child protective services reporting applies to children currently at risk of harm; there are no children in the home, and a future pregnancy alone does not trigger mandatory reporting.
• D. Refusing care is unethical, abandons the patient, and does not serve her safety or well-being.